Skip to main content
  • English
  • Français
  • About Us
    • About Us
    • Our Purpose and Identity
    • Integrated Report 2021
    • Governance
      • Governance
      • Board of Directors
      • Executive Committee
    • Where we are
    • Through time
    • All Our Stories
      • All Our Stories
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
  • Your Health
    • Your Health
    • Health and Well-Being
    • Diabetes and Cardiovascular Diseases
    • Specialty Care
      • Specialty Care
      • Rare Diseases
      • Rare Blood Disorders
      • Neurology
      • Immunology
      • Oncology
        • Oncology
        • When Cancer Grows Old
          • When Cancer Grows Old
          • Contributions Initiative
          • Global collaboration
      • Patient Support
    • Vaccines
      • Vaccines
      • The Value of vaccines
      • How immunization works
      • Infectious Disease and Vaccines
        • Infectious Disease and Vaccines
        • COVID-19
        • Influenza
        • Meningococcal Meningitis
        • Pertussis
        • Poliomyelitis
        • Respiratory Syncytial Virus
        • Discover more
      • Research and Innovation
      • Vaccines Production
      • Vaccines Stories
    • Taking Medicines Safely
    • Patient Safety at Sanofi
  • Science & Innovation
    • Science & Innovation
    • Partnering
      • Partnering
      • Let's partner
      • Areas of Interest
        • Areas of Interest
        • China & Emerging Markets
        • Digital
        • General Medicines
        • Immunology
        • Neuroscience
        • Oncology
        • Out-Licensing
        • Rare Diseases
        • Technology Platforms
        • Vaccines
      • Meet the team
    • Research & Development
      • Research & Development
      • Sanofi Pipeline
      • Vaccines
      • Immunology and Inflammation
      • Neurology
      • Oncology
      • Pioneering Technology Platforms
        • Pioneering Technology Platforms
        • Genomic Medicine Technology Platform
        • mRNA Technology: Vaccines and Beyond
        • NANOBODY® Technology Platform
        • SYNTHORIN™ Technology Platform
      • Rare Blood Disorders R&D
      • Rare Diseases
      • Voices from the Lab
    • Clinical Trials & Results
      • Clinical Trials & Results
      • Phases
      • Our disclosure commitments
        • Our disclosure commitments
        • Sanofi Pharma
        • Sanofi Genzyme
        • Sanofi Pasteur
      • Our data sharing commitments
      • Managed Access Programs (MAPs)
      • Investigator Sponsored Studies and Externally Sponsored Collaboration
    • Collaboration & Awards
      • Collaboration & Awards
      • Europe
        • Europe
        • iAwards
        • iDEA-iTECH
      • North America
        • North America
        • iAwards
        • iDEA-iTECH
      • China
    • Science Stories
  • Our Responsibility
    • Our Responsibility
    • Access to Quality Healthcare – Sanofi Global Health
    • Environmental sustainability
    • Diversity, Equity and Inclusion
      • Diversity, Equity and Inclusion
      • Making an Impact
      • A Million Conversations
      • Global Poll
      • Board & Employee Groups
      • Gender Balance
        • Gender Balance
        • Women@Sanofi
      • Our Partners
      • Our LGBTQ+ Voice
    • Healthcare for all
      • Healthcare for all
      • Sanofi Humanitarian Aid Programs
      • Contributing to the eradication, elimination and control of some infectious diseases
      • Fighting Against Falsified Medicine
      • Serving the needs of patients with non-communicable diseases
    • Corporate Citizenship
    • Foundation S (Endowment Fund)
    • Ethics & Transparency
      • Ethics & Transparency
      • Patient Safety at Sanofi
      • Our Code of Conduct
    • Suppliers
    • Document center
      • Document center
      • All factsheets
      • Access to Healthcare and Pricing
      • Country reports and other documents
      • CSR Strategy and Value Creation
      • Duty of Vigilance incl. Supply Chain
      • Environment
      • Ethics and Transparency
      • Governance, Controls and Procedures
      • Reporting Frameworks and Indicators
      • Social incl. Communities
  • |
  • Careers
    • Careers
    • Explore our career opportunities
    • A range of possibilities
      • A range of possibilities
      • Market access
      • Marketing
      • Medical
      • Production
      • Research & Development
      • Consumer Healthcare
      • Vaccines careers
      • Student / Graduate / Young Professionals
      • Discover more possibilities
    • Grow with us
      • Grow with us
      • Diversity & Inclusion
      • Development opportunity: how Sanofi empowers you
      • Benefits
  • Investors
    • Investors
    • Company overview
      • Company overview
      • Financial reporting center & Key data
      • Fixed income
    • Financial results and events
      • Financial results and events
      • Quarterly earnings at a glance
      • Investor presentations
      • Annual General Meetings
      • Broker conferences
    • Environmental, Social, Governance
      • Environmental, Social, Governance
      • Our Double Materiality Assessment
      • ESG Newsletters
    • Corporate governance
      • Corporate governance
      • Governance
      • Board of Directors
      • Executive Committee
      • Specialist committees
      • Compensations
      • Standards & rules
      • Regulated agreements
      • Internal Control
    • Sanofi share and ADRs
      • Sanofi share and ADRs
      • Share overview
        • Share overview
        • Shares & voting rights
        • Share repurchases
      • Sanofi stock chart
      • Shareholding calculator
      • Dividends
      • ADRs
      • Shareholding structure
      • Vara consensus
    • Reports and publications
      • Reports and publications
      • Financial and CSR reports
      • Shareholder publications
    • Individual Shareholders
      • Individual Shareholders
      • Welcome to Sanofi
      • Being a shareholder
        • Being a shareholder
        • Five reasons to be a Sanofi shareholder
        • How to buy Sanofi shares
        • Registered shares
      • Shareholder events
        • Shareholder events
        • Financial Calendar
        • Annual General Meetings
        • Participate in General Meetings
      • Reports and publications
        • Reports and publications
        • Financial and CSR reports
        • Shareholder publications
      • Shareholders committee
    • Regulated information
    • Contacts
  • Media
    • Media
    • Press releases
      • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Articles
      • Articles
      • 2019
    • Contacts
    • Media Alert
  • |
  • Paris 2024 Partnership
Worldwide
EN
  • EN
  • FR
  • Home
  • Media
  • Press releases
  • 2015
December 28, 2015
Press releases
Dengvaxia® First Dengue Vaccine Approved in Brazil
December 23, 2015
Press releases
Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
December 22, 2015
Press releases
Sanofi Pasteur's Dengue Vaccine Approved in the Philippines
December 15, 2015
Press releases
Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Anima...
December 9, 2015
Press releases
Sanofi: Dengvaxia®, World's First Dengue Vaccine, Approved in Mexico
November 30, 2015
Press releases
Sanofi: First Doses of Injectable Polio Vaccine ShanIPV(TM) Soon Available for Indian Infants
November 24, 2015
Press releases
Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled
November 20, 2015
Press releases
Sanofi and AstraZeneca Exchange More Than 200,000 Chemical Compounds
November 19, 2015
Press releases
Sanofi Announces Commitment to COP21
November 18, 2015
Press releases
Xavier Darcos appointed President of the Sanofi Espoir Foundation
November 9, 2015
Press releases
Sanofi Pasteur Reveals its Research on a "Universal" Influenza Vaccine
November 8, 2015
Press releases
Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
November 6, 2015
Press releases
Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
November 6, 2015
Press releases
Sanofi Sets Out Strategic Roadmap for Long-term Growth
November 5, 2015
Press releases
Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
November 4, 2015
Press releases
Sanofi and the Institut Pasteur reward four researchers for their major contributions in the service of health
November 3, 2015
Press releases
Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement
October 29, 2015
Press releases
Sanofi grew sales and business EPS(1) in Q3 2015
October 8, 2015
Press releases
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials
October 7, 2015
Press releases
Sanofi: New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
October 1, 2015
Press releases
Sanofi: Genzyme Opts into Alnylam's ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe
September 29, 2015
Press releases
Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
September 28, 2015
Press releases
Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®
September 28, 2015
Press releases
Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
September 16, 2015
Press releases
Sanofi's CSR Achievements Recognized in the Dow Jones Sustainability Indices
September 15, 2015
Press releases
Sanofi successfully prices EUR 2.0 billion bond issue
September 14, 2015
Press releases
Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study
September 1, 2015
Press releases
Sanofi and Regeneron Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
August 31, 2015
Press releases
Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes
August 10, 2015
Press releases
Sanofi, Evotec and Apeiron Biologics Enter Collaboration To Develop Novel Small Molecule Immuno-Oncology Treatments
August 7, 2015
Press releases
Sanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies
July 31, 2015
Press releases
Sanofi : Online Availability of Sanofi Group's Half-Year Financial Report for 2015
July 30, 2015
Press releases
Sanofi delivers solid sales and business EPS(1) growth in Q2 2015
July 29, 2015
Press releases
Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint
July 28, 2015
Press releases
Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration
July 27, 2015
Press releases
New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue
July 27, 2015
Press releases
Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca
July 24, 2015
Press releases
Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
July 24, 2015
Press releases
Sanofi and Regeneron Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia
July 15, 2015
Press releases
Sanofi Announces New, Global Business Unit Structure to Drive Future Growth
July 10, 2015
Press releases
Sanofi: Merial Introduces Oravet® Dental Hygiene Chews for Dogs
July 9, 2015
Press releases
Sanofi and Regeneron Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection
July 8, 2015
Press releases
Sanofi Extends Collaboration with Medicines for Malaria Venture to Fight One of the World's Deadliest Parasitic Diseases
July 3, 2015
Press releases
Sanofi's New Basal Insulin Lantus® XR, Known as Toujeo® in the U.S. and Europe, Approved in Japan for the Treatment of Diabetes Mellitus
July 2, 2015
Press releases
Sanofi Signs a Global Agreement with SUEZ environnement To Enhance Water and Waste Management
June 10, 2015
Press releases
FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
June 8, 2015
Press releases
Sanofi's Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk
June 6, 2015
Press releases
Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes
June 4, 2015
Press releases
Sanofi: FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa
May 28, 2015
Press releases
Sanofi Hosts German Chancellor Angela Merkel at Frankfurt Site
Sanofi

    Follow us

  • Contact
  • Legal notice
  • Privacy & Data Protection
  • Cookies policy
  • Corporate code of ethics
  • Our publications
  • Sitemap
  • Our websites
  • Accessibility: partial compliance

© Sanofi 2004-2022 - All rights reserved

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED